Saving Lives Through Innovation

Chrysalis BioTherapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of treatments for serious respiratory disorders and acute radiation exposure

Our Innovative Solutions

TP508 Peptide Technology

The TP508 thrombin peptide is released locally following vascular injury to initiate cellular regenerative processes that lead to revascularization, stem cell activation, and tissue repair.


TP508, targets endothelial cells to restore vascular function and modulate immune responses
after injury. A single injection of TP508 24 hours after SARS-CoV-2 infection almost completely
blocks the CoV-2 virus-induced cytokine storm in animal models.

Respiratory Failure (ARDS)

Acute respiratory distress syndrome (ARDS) affects more than 3 million people each year globally and ~180,000 patients in the US, accounting for 10% of intensive care unit admissions, of which the mortality rate is ~30%.

Solution for Nuclear Radiation Exposure

A single TP508 injection 24 hours after a lethal dose of whole body radiation significantly increases survival and reduces delayed effects of radiation.

Chrysalis BioTherapeutics, Inc.

Chrysalis is pioneering the use of natural regenerative peptides to restore vascular function and activate normal stem cell populations where they exist in the body to accelerate tissue repair and prevent damaging effects of trauma, disease, ischemia, and radiation exposure

transparent header image
The Problem

There is an urgent unmet clinical need for a drug to prevent mortality caused by acute respiratory distress syndrome (ARDS) caused by COVID-19 and non-COVID-related infection, inflammation, or traumatic injury.  The immediate target indication for TP508 is to treat mild to moderate ARDS patients to reduce mortality and reverse systemic effects on lung, heart, brain and kidney such as that seen in long-COVID (long-haulers) patients

TP508 Clinical Pipeline
a picture 11
Pre-Clinical Studies
IND Enabling Studies/cGMP Manufacturing
Phase 1/2
Moderate/Severe Covid-19
Brain Cancer Radiation Therapy
Traumatic Brain Injury
Nuclear Countermeasure/Acute Exposure